Osimertinib
EGFR Activating Mutation
Tianjin Medical University Cancer Institute and HospitalSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the EGFR Activating Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Juntendo University | Phase 4 | BB |
ty-9591 TYK Medicines, Inc | Phase 3 | BB |
Gefetinib Sichuan University | Phase 4 | BB |
Famitinib Tianjin Medical University Cancer Institute and Hospital | Phase 3 | BB |
Nivolumab University of Washington | Phase 2 | B |
View all 21 →
Same molecule, other indications
Osimertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →